

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Ketamine and rapid-acting antidepressants: a new... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/7-659/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/7-659" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide" />
    
            <meta name="og:title" content="F1000Research Article: Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide.">
            <meta name="og:description" content="Read the latest article version by Ronald S. Duman, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="15607">
            <meta name="article-id" content="14344">
            <meta name="dc.title" content="Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide">
            <meta name="dc.description" content="Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications.">
            <meta name="dc.subject" content="Ketamine, mTOR, antidepressants, depression, suicide ">
            <meta name="dc.creator" content="Duman, Ronald S.">
            <meta name="dc.date" content="2018/05/24">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.14344.1">
            <meta name="dc.source" content="F1000Research 2018 7:659">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Ketamine">
            <meta name="prism.keyword" content="mTOR">
            <meta name="prism.keyword" content="antidepressants">
            <meta name="prism.keyword" content="depression">
            <meta name="prism.keyword" content="suicide ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2018/05/24">
            <meta name="prism.volume" content="7">
            <meta name="prism.number" content="659">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.14344.1">
            <meta name="prism.url" content="https://f1000research.com/articles/7-659">
            <meta name="citation_title" content="Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide">
            <meta name="citation_abstract" content="Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications.">
            <meta name="citation_description" content="Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications.">
            <meta name="citation_keywords" content="Ketamine, mTOR, antidepressants, depression, suicide ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Ronald S. Duman">
            <meta name="citation_author_institution" content="Department of Psychiatry, Laboratory of Molecular Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA">
            <meta name="citation_publication_date" content="2018/05/24">
            <meta name="citation_volume" content="7">
            <meta name="citation_publication_number" content="659">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.14344.1">
            <meta name="citation_firstpage" content="659">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/7-659/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/7-659.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=15607 /> <input type=hidden id=articleId name=articleId value=14344 /> <input type=hidden id=xmlUrl value="/articles/7-659/v1/xml"/> <input type=hidden id=xmlFileName value="-7-659-v1.xml"> <input type=hidden id=article_uuid value=86324d24-a4b1-425c-88fd-b613eccabdc8 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.14344.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.14344.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/7-659"
  },
  "headline": "Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide",
  "datePublished": "2018-05-24T12:55:31",
  "dateModified": "2018-05-24T12:55:31",
  "author": [
    {
      "@type": "Person",
      "name": "Ronald S. Duman"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/7-659/v1",
            "name": "Ketamine and rapid-acting antidepressants: a new era in the battle..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Ketamine and rapid-acting antidepressants: a new era in the battle... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=15607 data-id=14344 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14344.1" data-recommended="" data-doi="10.12688/f1000research.14344.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/7-659/v1/pdf?article_uuid=86324d24-a4b1-425c-88fd-b613eccabdc8" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-14344-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-14344-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-14344-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):659 (<a class=new-orange href="https://doi.org/10.12688/f1000research.14344.1" target=_blank>https://doi.org/10.12688/f1000research.14344.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-14344-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=14344 id=track-article-signin-14344 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14344?target=/articles/7-659/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15607 /> <input name=articleId type=hidden value=14344 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:ronald.duman@yale.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ronald S. Duman</span></a><a href="https://orcid.org/0000-0001-8690-8439" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8690-8439</div></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:ronald.duman@yale.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Ronald S. Duman</span></a><a href="http://orcid.org/0000-0001-8690-8439" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0001-8690-8439</div></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 24 May 2018 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.14344.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Psychiatry, Laboratory of Molecular Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA<br/> <p> <div class=margin-bottom> Ronald S. Duman <br/> <span>Roles: </span> Formal Analysis </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=34698-34249></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=34699-34250></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=34697-34248></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has invigorated the field. In addition to these remarkable actions, ketamine has proven effective for the treatment of suicidal ideation. Efforts are under way to develop ketamine-like drugs with fewer side effects as well as agents that act at other sites within the glutamate neurotransmitter system. This includes ketamine metabolites and stereoisomers, drugs that act as NMDA allosteric modulators or that block mGluR2/3 autoreceptors. In addition, targets that enhance glutamate neurotransmission or synaptic function (or both), which are essential for the rapid and sustained antidepressant actions of ketamine in rodent models, are being investigated; examples are the muscarinic cholinergic antagonist scopolamine and activators of mechanistic target of rapamycin complex 1 (mTORC1) signaling, which is required for the actions of ketamine. The discovery of ketamine and its unique mechanisms heralds a new era with tremendous promise for the development of novel, rapid, and efficacious antidepressant medications. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Ketamine, mTOR, antidepressants, depression, suicide </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Ronald S. Duman (<a href="mailto:ronald.duman@yale.edu">ronald.duman@yale.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Ronald S. Duman </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The author has received consulting fees from Taisho, Johnson & Johnson, and Naurex and grant support from Taisho, Johnson & Johnson, Naurex, Allergan, Navitor, Lundbeck, Relmada, and Eli Lilly and Company. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> This research was supported by National Institute of Mental Health grants MH045481 and MH093897 and the State of Connecticut.<br><br>The funders had no role in decision to publish, or preparation of the manuscript.<br> <br/> </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2018 Duman RS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):659 (<a href="https://doi.org/10.12688/f1000research.14344.1" target=_blank>https://doi.org/10.12688/f1000research.14344.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 24 May 2018, <b>7</b>(F1000 Faculty Rev):659 (<a href="https://doi.org/10.12688/f1000research.14344.1" target=_blank>https://doi.org/10.12688/f1000research.14344.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 24 May 2018, <b>7</b>(F1000 Faculty Rev):659 (<a href="https://doi.org/10.12688/f1000research.14344.1" target=_blank>https://doi.org/10.12688/f1000research.14344.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d10202e143>Introduction</h2><p class="" id=d10202e146>Major depressive disorder affects nearly 20% of the population at some point during the life span and is estimated to be the number one cause of disability by 2020<sup><a href="#ref-1">1</a>–<a href="#ref-4">4</a></sup>. The deleterious effects of depression are compounded by the lack of fast and efficacious treatment regimens, as currently available medications are effective in only about two-thirds of patients and there is a significant therapeutic time lag of weeks to months<sup><a href="#ref-5">5</a></sup>. The efficacy and time lag limitations of current medications are particularly problematic for a patient population at elevated risk for suicide, which has increased significantly over the past 4 years<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>.</p><p class="" id=d10202e167>These deficiencies highlight a major unmet need for the treatment of depression and underscore the impact of new rapid-acting antidepressant agents, notably the NMDA receptor antagonist ketamine. A single subanesthetic dose of ketamine produces a therapeutic response within a few hours that lasts for about 7 days<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. Equally surprising is that ketamine is effective in severely depressed patients who are considered treatment-resistant (that is, patients who have failed to respond to two or more typical antidepressants). In addition, ketamine has proven effective for the rapid reduction of suicide ideation<sup><a href="#ref-10">10</a></sup>. The discovery of the rapid, efficacious, and sustained effects of ketamine is arguably the greatest breakthrough in the field of depression in over 60 years since the development of the monoaminergic antidepressants in the 1950s.</p><p class="" id=d10202e181>Here, we will provide a brief history and overview of the discovery of ketamine and how it impacts the synaptic pathophysiology of depression and current evidence on the molecular and cellular mechanisms underlying the actions of ketamine. Then we will discuss how the ketamine discovery has stimulated the development of novel agents with fewer side effects, including drugs that act at the glutamate-NMDA receptor but also other agents that impact synapse number and function via other pathways.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10202e187>Discovery of ketamine and NMDA receptor antagonists as rapid-acting agents</h2><p class="" id=d10202e190>Most drug development efforts in the depression field have focused on the serotonin and norepinephrine neurotransmitter systems since the development of the monoamine reuptake blocker tricyclic antidepressants. However, studies of the glutamatergic neurotransmitter system and the mechanisms underlying synaptic plasticity stimulated drug development efforts in these areas. Early studies demonstrated that typical antidepressants altered the affinity of the NMDA receptor glycine site, suggesting the possibility that decreased NMDA receptor function contributes to an antidepressant response. This hypothesis was directly tested first by Krystal, Berman, Charney, and colleagues at Yale when they investigated a single subanesthetic dose (0.5 mg/kg, intravenous [IV] infusion over the course of 40 minutes) of ketamine and found that patients started reporting improvement of depressive symptoms within a matter of a few hours<sup><a href="#ref-8">8</a></sup>. These improvements occurred after the initial psychotic and dissociative effects of ketamine, which occur in the first 60 minutes. The rapid and efficacious antidepressant actions of ketamine were confirmed in a larger double-blind, placebo-controlled study by Zarate, Charney, and colleagues at the National Institute of Mental Health<sup><a href="#ref-9">9</a></sup> and subsequently by many other studies from a number of clinical research groups, largely erasing any doubts of the incredible antidepressant actions of ketamine<sup><a href="#ref-11">11</a>–<a href="#ref-13">13</a></sup>.</p><div class=section><a name=d10202e208 class=n-a></a><h3 class=section-title>Ketamine reverses the synaptic abnormalities caused by stress</h3><p class="" id=d10202e213>Glutamate and NMDA receptors play an important role in cellular models of learning and memory, notably long-term potentiation (LTP), characterized by sustained synaptic strengthening in response to prior high-frequency stimulation. Actions of ketamine at NMDA receptors could influence NMDA function and synaptic plasticity in brain regions implicated in depression<sup><a href="#ref-14">14</a></sup>. The possibility that synaptic changes are relevant to depression is supported by evidence that chronic stress, often used in rodent models of depression, causes significant loss of synapses and even retraction of apical dendrites in the prefrontal cortex (PFC) and hippocampus<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup> (<a href="#f1">Figure 1</a>). The relevance of stress-induced synaptic deficits in rodent models is in turn supported by evidence from brain imaging studies demonstrating decreased volume of PFC and hippocampus in depressed patients and post-mortem studies showing decreased synapse number<sup><a href="#ref-17">17</a></sup>. In contrast to the effects of chronic stress, we found that a single dose of ketamine rapidly increases the number and function of spine synapses in layer V pyramidal neurons in the medial PFC (mPFC) and rapidly reverses the synaptic deficits of these neurons caused by 3 weeks of chronic stress exposure<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup> (<a href="#f1">Figure 1</a>). Increased levels of synaptic proteins, including levels of glutamate AMPA receptor GluA1, were observed after 2 hours, consistent with the onset of the therapeutic actions of ketamine. These studies demonstrate that ketamine rapidly increases synaptic function in the mPFC and that this reverses the synaptic pathophysiology of depression<sup><a href="#ref-20">20</a></sup>.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15607/4f83c542-4add-4162-83fc-5d80fddeb639_figure1.gif"><img alt="4f83c542-4add-4162-83fc-5d80fddeb639_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15607/4f83c542-4add-4162-83fc-5d80fddeb639_figure1.gif"></a><div class=caption><h3>Figure 1. Schematic model for the initial cellular target sites of rapid-acting antidepressants and subsequent synaptic changes.</h3><p id=d10202e259>Stress and depression cause neuronal atrophy and decreased synapse number in the medial prefrontal cortex (PFC) and hippocampus that is associated with the depressive symptoms and behaviors in rodent models. Conversely, fast-acting antidepressants like ketamine rapidly increase synapse number and function and reverse the synaptic deficits caused by chronic stress. The synaptic actions of ketamine, as well as several other agents (that is, esketamine, [2R,6R]-hydroxynorketamine, mGluR2/3 antagonists LY341,495 and MGS0039, and scopolamine acting at acetylcholine muscarinic 1 receptors), are activity-dependent and are thought to result from a burst of glutamate via blockade of receptors on tonic firing GABA interneurons, resulting in disinhibition of glutamate transmission. This burst of glutamate causes activity-dependent release of brain-derived neurotrophic factor (BDNF), stimulation of TrkB-Akt and mechanistic target of rapamycin complex 1 (mTORC1) signaling, and rapid increases in synaptic protein synthesis that underlie new synapse formation. Negative allosteric modulators, including CP-101,606, CERC-301, and Ro 25-6981 agents like rapastinel, may increase synapse formation by enhancing NMDA function and thereby increasing BDNF release and downstream mTORC1 signaling. A role for mTORC1 is further supported by evidence that an agent that increases mTORC1 activity also produces synaptic and rapid antidepressant responses. In addition to these sites, there is evidence that the GABA<sub>A</sub>-positive allosteric modulating agents brexanolone and SAGE-217 also produce rapid antidepressant responses. The intersection of these agents with the mechanisms underlying the rapid response to glutamatergic agents remains to be identified.</p></div></div><p class="" id=d10202e269>In addition to the effects of ketamine in the mPFC, there is a recent high-impact report demonstrating the effects of ketamine in the lateral habenula, a region that inhibits the major reward centers in the brain<sup><a href="#ref-21">21</a></sup>. This study shows that depressive-like behavior in rodent models (rat congenital learned helplessness [LH] and mouse chronic restraint stress) is characterized by increased burst firing of neurons in the lateral habenula, which causes inhibition of the activity of the major reward and emotion pathways and the ventral tegmental dopamine system as well as the serotonin dorsal raphe neurons. This burst firing is driven by NMDA receptor activity as well as low-voltage-sensitive T-type calcium channels; ketamine, after either systemic or local intracerebral administration, is sufficient to block the burst firing and depressive behavior in the LH rats. It has been postulated that blockade of the anti-reward effects exerted by the lateral habenula could underlie the rapid antidepressant actions of ketamine and that the synaptic effects of ketamine in the mPFC could be more related to the sustained actions of ketamine, although further studies are needed to test this hypothesis.</p></div><div class=section><a name=d10202e277 class=n-a></a><h3 class=section-title>Mechanisms underlying the synaptic actions of ketamine: disinhibition hypothesis</h3><p class="" id=d10202e281>How might ketamine, an NMDA receptor channel blocker, cause a rapid increase in the number and function of spine synapses? There are different theories, but the one that has received the most attention is that ketamine actually increases glutamate transmission and causes an LTP-like enhancement of synapse formation in the mPFC<sup><a href="#ref-14">14</a></sup>. This idea was first formulated when it was discovered that ketamine rapidly (30 minutes after systemic administration) increases extracellular glutamate in the mPFC of rodents<sup><a href="#ref-22">22</a></sup>; this effect was observed only at low subanesthetic doses of ketamine, whereas high anesthetic doses had no effect. Elevation of extracellular glutamate led to the hypothesis that low doses of ketamine selectively block NMDA receptors on GABA interneurons that inhibit glutamate transmission (<a href="#f1">Figure 1</a>). This selectivity is based on the fact that GABA interneurons are tonic firing, which results in removal of the Mg<sup>2+</sup> block of the NMDA receptor channel, allowing ketamine to enter, bind, and block the channel. Direct evidence for the disinhibition hypothesis has been reported recently in slice studies of hippocampus, which show that low concentrations of ketamine decrease inhibitory input onto pyramidal neurons and thereby lead to an increase in the synaptic drive of excitatory pyramidal neurons in the hippocampus<sup><a href="#ref-23">23</a></sup>. There is also an opposing “direct” hypothesis that the synaptic actions of ketamine are mediated by blockade of NMDA receptors on excitatory neurons, which leads to homeostatic control of synaptic activity<sup><a href="#ref-24">24</a></sup>. This homeostatic direct hypothesis is difficult to rationalize in the mPFC where there is a glutamate burst but could occur in other brain regions where there is no increase in glutamate.</p><p class="" id=d10202e307>Studies of the cellular signaling mechanisms underlying the synaptic actions of ketamine demonstrate a requirement for brain-derived neurotrophic factor (BDNF) and activation of pathways that increase the synthesis of synaptic proteins (<a href="#f1">Figure 1</a>). The antidepressant actions of ketamine are blocked in conditional BDNF-knockout mice<sup><a href="#ref-24">24</a></sup> and in mice with a knockin of the BDNF Val66Met allele, which blocks the processing- and activity-dependent release of BDNF<sup><a href="#ref-25">25</a></sup>. Further evidence that activity-dependent release of BDNF is required comes from studies demonstrating that infusion of a function-blocking antibody into the mPFC blocks the antidepressant actions of ketamine<sup><a href="#ref-26">26</a></sup>. Increased synthesis of synaptic proteins occurs via regulation of the mechanistic target of rapamycin complex 1 (mTORC1) as well as eukaryotic elongation factor 2 kinase (eEF2K). We have found that ketamine rapidly increases the phosphorylation of mTOR and downstream signaling proteins that stimulate synaptic protein synthesis and that the behavioral actions of ketamine are blocked by infusion of rapamycin, a selective inhibitor of mTORC1<sup><a href="#ref-18">18</a></sup> (<a href="#f1">Figure 1</a>). Further evidence for mTORC1 is provided by recent studies demonstrating that direct stimulation of mTORC1 also produces rapid synaptic and antidepressant behavioral responses<sup><a href="#ref-27">27</a></sup>. Ketamine stimulation of mTORC1 signaling has been replicated in multiple laboratories<sup><a href="#ref-18">18</a>,<a href="#ref-19">19</a>,<a href="#ref-28">28</a>–<a href="#ref-42">42</a></sup>, although there is a preliminary report of non-significant effects, raising a concern about the suitability of this target for drug screening<sup><a href="#ref-43">43</a></sup>. An alternative hypothesis is that ketamine blockade of NMDA receptors at rest results in deactivation of eEF2K and de-suppression of translation, thereby increasing BDNF expression in pyramidal neurons<sup><a href="#ref-24">24</a></sup>. There has also been evidence that ketamine influences the opioid system and inflammation processes, effects that could contribute to the actions of ketamine<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10202e369>Development of novel glutamate/NMDA receptor agents for depression</h2><p class="" id=d10202e372>The widespread use of ketamine for the treatment of depression is limited by its psychotomimetic and dissociative side effects as well as abuse potential. Nevertheless, for treatment-resistant patients, ketamine may be the only choice and is becoming more widely available. Another limitation is that ketamine is administered primarily by an IV route in a clinic or hospital setting. To address this issue, Johnson &amp; Johnson is developing a nasal application of the (S)-ketamine stereoisomer (esketamine), which has received breakthrough therapy classification from the US Food and Drug Administration (FDA). Esketamine acts similarly to ketamine and has higher affinity as an NMDA channel blocker than the (R)-isomer (<a href="#f2">Figure 2</a>). Early clinical trials have been promising, and although esketamine has side effects similar to those of ketamine, it could be approved as a nasal application as early as the beginning of 2019. Surprisingly, clinical trials with other non-selective NMDA receptor antagonists, including memantine and lanicemine, have been largely negative<sup><a href="#ref-46">46</a>–<a href="#ref-48">48</a></sup>. The reason for the lack of efficacy is not clear but could be related to the dose used or the efficacy (or both) of the channel-blocking activity of these agents.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/15607/4f83c542-4add-4162-83fc-5d80fddeb639_figure2.gif"><img alt="4f83c542-4add-4162-83fc-5d80fddeb639_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/15607/4f83c542-4add-4162-83fc-5d80fddeb639_figure2.gif"></a><div class=caption><h3>Figure 2. Model of the NMDA receptor complex and target sites of rapid-acting antidepressants.</h3><p id=d10202e395>The NMDA receptor is a complex of four subunits comprising four subunits that form a pore that is permeable to Ca<sup>2+</sup>. At resting state, the pore is blocked by Mg<sup>2+</sup>, but, upon depolarization, Mg<sup>2+</sup> is removed, allowing entry of Ca<sup>2+</sup>. In the open state, the pore is also accessible by ketamine, which enters and blocks further Ca<sup>2+</sup> influx. The (S)-enantiomer esketamine binds to the same site to block the channel. There are several known sites for regulation of the NMDA receptor in addition to the ketamine and glutamate/NMDA binding sites. Glycine binds to the GluN1 subunit and enhances NMDA receptor function; AV-101 is an antagonist of the glycine B co-agonist site. Rapastinel has glycine-like enhancing properties, although it binds to an allosteric site on the complex. There are several GluN2B-selective allosteric modulators that have potential as rapid-acting agents, including CP-101,606, CERC-301, and Ro 25-6981. It is currently unknown what the initial target is for the metabolite (2R,6R)-hydroxynorketamine.</p></div></div><div class=section><a name=d10202e417 class=n-a></a><h3 class=section-title>Stereoisomers and metabolites of ketamine</h3><p class="" id=d10202e422>Efforts have also continued to develop and identify agents with the rapid and efficacious actions of ketamine but with fewer or no side effects. There is evidence from rodent studies that the (R)-stereoisomer of ketamine also produces rapid antidepressant effects in rodent models but without the ketamine-like side effects on sensory motor gating or conditioned place preference<sup><a href="#ref-49">49</a></sup>. The reduced side effects may be related to the decreased affinity of the (R)-isomer for the NMDA receptor. In addition, (S)- but not (R)-ketamine is reported to stimulate mTORC1 signaling<sup><a href="#ref-42">42</a></sup>. There is also evidence that the ketamine metabolite (2R,6R)-hydroxynorketamine—(2R,6R)-HNK—produces rapid and sustained antidepressant actions in several rodent models, again without influencing sensory motor gating or conditioned place preference<sup><a href="#ref-50">50</a></sup>. This study found that (2R,6R)-HNK increased AMPA-GluA1 receptor expression and activity and increased levels of BDNF and phosphorylation of eEF2K; we have also found that the behavioral actions of (2R,6R)-HNK are blocked in BDNF Val66Met mice or by infusion of a function-blocking antibody and by infusion of rapamycin into the mPFC<sup><a href="#ref-51">51</a></sup>. However, others have reported that the antidepressant actions of (2R,6R)-HNK are less potent and stable compared with (R)-ketamine<sup><a href="#ref-52">52</a></sup> or do not produce antidepressant actions in a rat LH model<sup><a href="#ref-53">53</a></sup>. Zanos and colleagues<sup><a href="#ref-50">50</a></sup> report that they could find no evidence that (2R,6R)-HNK blocks NMDA receptors, including binding to known sites on the receptor complex or NMDA activity in hippocampal slices, so the initial cellular trigger remains to be identified. Nevertheless, another study reported that a high concentration of (2R,6R)-HNK (50 µM) produces partial blockade of synaptic NMDA receptors and downstream signaling compared with the same concentration of ketamine<sup><a href="#ref-54">54</a></sup>.</p></div><div class=section><a name=d10202e459 class=n-a></a><h3 class=section-title>Other glutamatergic agents: GluN2B and mGluR2/3 antagonists and rapastinel</h3><p class="" id=d10202e464>There is also evidence from rodent studies and preliminary clinical trials that antagonists that are selective for the GluN2B subunit of the NMDA receptor have antidepressant efficacy (<a href="#f2">Figure 2</a>). Clinical studies first reported that a single dose of the selective GluN2B antagonist CP101,606 produces antidepressant actions in depressed patients, although significant effects were not observed until 5 days later<sup><a href="#ref-55">55</a></sup>. Recent clinical studies with another GluN2B-selective agent, CERC-301, have been mixed; early studies reported positive effects, and a more recent report was negative, although this could be because of the lower dose used for the latter study<sup><a href="#ref-56">56</a></sup>. Rodent studies demonstrate that a single dose of the GluN2B antagonist Ro 25-6981 produces antidepressant actions in several different antidepressant models, including the forced swim test (FST), LH, and novelty suppressed feeding test (NSFT), as well as in the chronic unpredictable stress-anhedonia model<sup><a href="#ref-18">18</a>,<a href="#ref-57">57</a></sup>. Additional studies are needed to further test the efficacy and rapid actions of GluN2B-selective agents.</p><p class="" id=d10202e485>Another agent of interest is rapastinel, also referred to as GLYX-13, which was initially thought to act as an NMDA glycine site partial agonist (<a href="#f2">Figure 2</a>). More recent studies indicate that rapastinel has activity that is similar to that of a glycine site partial agonist but acts via an allosteric site<sup><a href="#ref-58">58</a></sup>. Preclinical studies demonstrate that a single dose of rapastinel results in antidepressant actions in several rodent models, including the FST, NSFT, LH, chronic mild stress/anhedonia, and social defeat stress<sup><a href="#ref-27">27</a>,<a href="#ref-59">59</a></sup>. In contrast to ketamine, rapastinel does not influence sensory motor gating or conditioned place preference. A single dose of rapastinel also increases synapse number and function in the mPFC and requires BDNF release and mTORC1 activation<sup><a href="#ref-27">27</a>,<a href="#ref-41">41</a></sup>. However, one study reports that the antidepressant actions of rapastinel in a social defeat model as well as its effects on BDNF-TrkB signaling are not as long-lasting as those of (R)-ketamine<sup><a href="#ref-60">60</a></sup>. A double-blind randomized clinical trial reported that a single dose of rapastinel produces antidepressant actions that persisted for about 7 days<sup><a href="#ref-61">61</a></sup>. Rapastinel has received breakthrough classification and currently is in phase III clinical trials. Another agent that works via the glycine site is AV-101, a prodrug (L-4-chlorokynurenine) that is transported into the brain where it is converted to 7-chlorokynurenic acid, a potent antagonist of the glycine B coagonist site of the NMDA receptor<sup><a href="#ref-62">62</a></sup>; AV-101 is in phase II clinical trials and has received fast-track status from the FDA.</p><p class="" id=d10202e522>Based on evidence that the actions of ketamine occur via a “glutamate burst” and the subsequent enhancement of synaptic function, other approaches to increase glutamate neurotransmission have been tested. Most notable are the metabotropic GluR2/3 antagonists, which increase glutamate activity by blocking presynaptic autoreceptors (<a href="#f1">Figure 1</a>). Preclinical studies have reported that mGluR2/3 antagonists, notably LY341,495 and MGS0039, produce antidepressant effects in a number of rodent models, including the FST, NSFT, and a chronic unpredictable stress-anhedonia model, and also require mTORC1 signaling<sup><a href="#ref-29">29</a>,<a href="#ref-63">63</a>,<a href="#ref-64">64</a></sup>. Clinical trials are needed to determine whether blockade of mGluR2/3 receptors produces a therapeutic response in patients and to determine the side effect profile of these agents.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10202e542>Additional rapid-acting antidepressant approaches</h2><p class="" id=d10202e545>Although drug development has focused on direct-acting glutamatergic approaches, there is evidence for other initial targets that produce rapid antidepressant responses, although some of these also indirectly influence glutamate transmission. The most notable of these is scopolamine, a non-selective acetylcholine muscarinic (AChM) receptor antagonist, which has shown promise in clinical trials. These studies have reported that a single low dose (4 µg/kg IV) of scopolamine produces an antidepressant response at the first assessment time point, 3 days after dosing, and there is anecdotal evidence of improvement within 24 hours<sup><a href="#ref-65">65</a>,<a href="#ref-66">66</a></sup>. These rapid therapeutic actions led us to examine the cellular actions of scopolamine in rodent models. These studies showed that, like ketamine, scopolamine causes a rapid burst of glutamate in the mPFC and increases mTORC1 signaling and synapse formation and that the antidepressant actions of scopolamine require BDNF release and mTORC1<sup><a href="#ref-67">67</a>,<a href="#ref-68">68</a></sup> (<a href="#f1">Figure 1</a>). We have also found that the antidepressant actions of scopolamine occur through blockade of AChM1 receptors on GABA interneurons, demonstrating that scopolamine acts via a disinhibition mechanism<sup><a href="#ref-69">69</a></sup>. Despite these interesting findings, there has been less interest in developing AChM antagonists for the treatment of depression relative to ketamine and direct-acting glutamatergic agents.</p><p class="" id=d10202e569>Another indirect approach that influences glutamate transmission is via the regulation of GABA<sub>A</sub> receptors, particularly selective inverse agonists that would increase glutamate transmission. Rodent studies targeting the α5-subunit-containing GABA<sub>A</sub> receptor, which is enriched in the PFC and hippocampus, report that a single dose of the α5-selective inverse agonists L-655,708 or MRK-016 produce rapid antidepressant behavioral responses in a number of tests, including the FST and female urine sniffing test (FUST), and chronic restraint stress and chronic unpredictable stress-anhedonia models<sup><a href="#ref-70">70</a>,<a href="#ref-71">71</a></sup>. The actions of these inverse agonists require AMPA receptor activity, indicating an increase in glutamate transmission as expected. These compounds lack the side effects of ketamine on sensory motor gating and conditioned place preference, and this is possibly due to the restricted expression of α5-subunit-containing GABA<sub>A</sub> receptors. Clinical studies are required to determine the therapeutic potential and to confirm the reduced side effect profile of these agents.</p><p class="" id=d10202e588>One other very different approach is based on evidence that ketamine and several other rapid-acting agents increase mTORC1 signaling in the mPFC. The biotech company Navitor has developed an agent, NV-5138, that stimulates mTORC1 signaling via binding to sestrin, an upstream regulatory pathway<sup><a href="#ref-72">72</a></sup> (<a href="#f1">Figure 1</a>). We have found that a single oral dose of NV-5138 increases mTORC1 signaling in the mPFC as expected and produces rapid antidepressant actions in the FST, NSFT, FUST, and chronic unpredictable stress-anhedonia models<sup><a href="#ref-27">27</a></sup>. These behavioral actions of NV-5138 are long-lasting (up to 7 days). In addition, a single dose of NV-5138 increases synapse number and function and levels of synaptic proteins in the mPFC. Preliminary studies also demonstrate that the actions of NV-5138 require BDNF (unpublished). Based on these promising preclinical findings, efforts are under way to test NV-5138 in human subjects and depressed patients.</p><p class="" id=d10202e602>Another exciting finding is the recent report that the neuroactive steroid allopregnanolone (SAGE-547, now referred to as brexanolone) produces rapid therapeutic actions in women with post-partum depression (PPD) (<a href="#f1">Figure 1</a>). Allopregnanolone is a positive allosteric modulator of synaptic and extrasynaptic GABA<sub>A</sub> receptors, particularly the δ-subunit that regulates tonic firing of GABA interneurons. PPD is associated with the precipitous drop at birth of allopregnanolone and other progesterone-derived neurosteroids that are very high during pregnancy; since PPD occurs in a subpopulation of women, there are likely vulnerability factors that are also involved. Previous studies have reported that mice with a deletion of the δ-subunit show depression-like behavior and abnormal maternal care during the post-partum period<sup><a href="#ref-73">73</a></sup>. The clinical study reports that sustained infusion (IV) of brexanolone results in a therapeutic response within 24–48 hours in severely depressed PPD women<sup><a href="#ref-74">74</a>,<a href="#ref-75">75</a></sup>. Brexanolone has received breakthrough status for the treatment of PPD and currently is in phase III trials. In addition, Sage has developed an orally available synthetic analogue, SAGE-217, that has shown therapeutic efficacy in both female and male patients with major depression; SAGE-217 has also received breakthrough therapy status and soon will be starting phase III trials.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10202e625>Future studies and drug development</h2><p class="" id=d10202e628>The discovery of ketamine and related agents holds tremendous promise for the rapid, efficacious treatment of depression. We are experiencing an unprecedented time of antidepressant drug development in this area; at least five different agents (rapastinel, esketamine, AV-101, brexanolone, and SAGE-217) have been awarded breakthrough therapy or fast-track status from the FDA. However, there are several critical problems to overcome. First, ketamine is a drug of abuse and has serious side effects, so new agents with a reduced side effect profile are needed. Second, although ketamine produces a rapid antidepressant response, the effects last for about 1 week, at which time patients typically relapse. New agents that can be used on a daily, sustained basis are needed. Third, studies are needed to understand why new ketamine-induced synapses are lost after 1 week and whether there are approaches or agents (or both) that can sustain the synaptic as well as the therapeutic actions of ketamine. Fourth, additional research is needed to fully understand the cellular mechanisms underlying the actions of ketamine and other rapid-acting agents and to determine the critical pathophysiological abnormalities that cause depression. The future for novel rapid-acting antidepressants looks very bright, as the drugs currently being tested in phase II and III clinical trials may address some of these issues. With continued efforts, there is hope that there will soon be a number of novel, rapid, and efficacious choices for the treatment of depression and the possibility that these could target the underlying causes of illness.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d10202e1 class=n-a></a><h2 class=main-title id=d10432>Competing interests</h2><p class=metadata-entry><a name=d10202e74 class=n-a></a><p id=d10202e75> The author has received consulting fees from Taisho, Johnson &amp; Johnson, and Naurex and grant support from Taisho, Johnson &amp; Johnson, Naurex, Allergan, Navitor, Lundbeck, Relmada, and Eli Lilly and Company.</p></p></div><div class=back-section><a name=d10202e1 class=n-a></a><h2 class=main-title id=d10434>Grant information</h2><p>This research was supported by National Institute of Mental Health grants MH045481 and MH093897 and the State of Connecticut.</p><p> <i>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</i> </p></div><div class=back-section><a name=d10202e635 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d10703>References</h2><div class="section ref-list"><a name=d10202e635 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d10202e642 class=n-a></a>WHO: WHO | Depression [Internet]. Depression. 2017. </span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718508444"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e651 class=n-a></a>Kessler RC, Chiu WT, Demler O, <i> et al.</i>: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. <i>Arch Gen Psychiatry.</i> 2005; <b>62</b>(6): 617–27. <a target=xrefwindow id=d10202e662 href="http://www.ncbi.nlm.nih.gov/pubmed/15939839">PubMed Abstract </a> | <a target=xrefwindow id=d10202e665 href="http://dx.doi.org/10.1001/archpsyc.62.6.617">Publisher Full Text </a> | <a target=xrefwindow id=d10202e669 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2847357">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718508444">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d10202e682 class=n-a></a>Kessler RC: The costs of depression. <i>Psychiatr Clin North Am.</i> 2012; <b>35</b>(1): 1–14. <a target=xrefwindow id=d10202e690 href="http://www.ncbi.nlm.nih.gov/pubmed/22370487">PubMed Abstract </a> | <a target=xrefwindow id=d10202e693 href="http://dx.doi.org/10.1016/j.psc.2011.11.005">Publisher Full Text </a> | <a target=xrefwindow id=d10202e696 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3292769">Free Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d10202e705 class=n-a></a>Murray CJ, Atkinson C, Bhalla K, <i> et al.</i>: The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. <i>JAMA.</i> 2013; <b>310</b>(6): 591–608. <a target=xrefwindow id=d10202e716 href="http://www.ncbi.nlm.nih.gov/pubmed/23842577">PubMed Abstract </a> | <a target=xrefwindow id=d10202e719 href="http://dx.doi.org/10.1001/jama.2013.13805">Publisher Full Text </a> | <a target=xrefwindow id=d10202e723 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5436627">Free Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/7030"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e732 class=n-a></a>Trivedi MH, Rush AJ, Wisniewski SR, <i> et al.</i>: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>Am J Psychiatry.</i> 2006; <b>163</b>(1): 28–40. <a target=xrefwindow id=d10202e743 href="http://www.ncbi.nlm.nih.gov/pubmed/16390886">PubMed Abstract </a> | <a target=xrefwindow id=d10202e746 href="http://dx.doi.org/10.1176/appi.ajp.163.1.28">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/7030">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d10202e760 class=n-a></a>Curtin SC, Warner M, Hedegaard H: Increase in Suicide in the United States, 1999–2014. <i>NCHS Data Brief.</i> 2016; (241): 1–8. <a target=xrefwindow id=d10202e765 href="http://www.ncbi.nlm.nih.gov/pubmed/27111185">PubMed Abstract </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d10202e774 class=n-a></a>National Violent Death Reporting System. CDC. 2015. <a target=xrefwindow id=d10202e776 href="https://www.cdc.gov/violenceprevention/nvdrs/index.html">Reference Source</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d10202e785 class=n-a></a>Berman RM, Cappiello A, Anand A, <i> et al.</i>: Antidepressant effects of ketamine in depressed patients. <i>Biol Psychiatry.</i> 2000; <b>47</b>(4): 351–4. <a target=xrefwindow id=d10202e796 href="http://www.ncbi.nlm.nih.gov/pubmed/10686270">PubMed Abstract </a> | <a target=xrefwindow id=d10202e799 href="http://dx.doi.org/10.1016/S0006-3223(99)00230-9">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/31404"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e808 class=n-a></a>Zarate CA Jr, Singh JB, Carlson PJ, <i> et al.</i>: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. <i>Arch Gen Psychiatry.</i> 2006; <b>63</b>(8): 856–64. <a target=xrefwindow id=d10202e819 href="http://www.ncbi.nlm.nih.gov/pubmed/16894061">PubMed Abstract </a> | <a target=xrefwindow id=d10202e822 href="http://dx.doi.org/10.1001/archpsyc.63.8.856">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/31404">F1000 Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731685411"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e835 class=n-a></a>Wilkinson ST, Ballard ED, Bloch MH, <i> et al.</i>: The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. <i>Am J Psychiatry.</i> 2018; <b>175</b>(2): 150–8. <a target=xrefwindow id=d10202e846 href="http://www.ncbi.nlm.nih.gov/pubmed/28969441">PubMed Abstract </a> | <a target=xrefwindow id=d10202e849 href="http://dx.doi.org/10.1176/appi.ajp.2017.17040472">Publisher Full Text </a> | <a target=xrefwindow id=d10202e853 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5794524">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731685411">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d10202e866 class=n-a></a>Sanacora G, Frye MA, McDonald W, <i> et al.</i>: A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry.</i> 2017; <b>74</b>(4): 399–405. <a target=xrefwindow id=d10202e877 href="http://www.ncbi.nlm.nih.gov/pubmed/28249076">PubMed Abstract </a> | <a target=xrefwindow id=d10202e880 href="http://dx.doi.org/10.1001/jamapsychiatry.2017.0080">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727783234"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e890 class=n-a></a>Wilkinson ST, Toprak M, Turner MS, <i> et al.</i>: A Survey of the Clinical, Off-Label Use of Ketamine as a Treatment for Psychiatric Disorders. <i>Am J Psychiatry.</i> 2017; <b>174</b>(7): 695–6. <a target=xrefwindow id=d10202e901 href="http://www.ncbi.nlm.nih.gov/pubmed/28669202">PubMed Abstract </a> | <a target=xrefwindow id=d10202e904 href="http://dx.doi.org/10.1176/appi.ajp.2017.17020239">Publisher Full Text </a> | <a target=xrefwindow id=d10202e908 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5549850">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727783234">F1000 Recommendation</a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d10202e921 class=n-a></a>Newport DJ, Carpenter LL, McDonald WM, <i> et al.</i>: Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. <i>Am J Psychiatry.</i> 2015; <b>172</b>(10): 950–66. <a target=xrefwindow id=d10202e932 href="http://www.ncbi.nlm.nih.gov/pubmed/26423481">PubMed Abstract </a> | <a target=xrefwindow id=d10202e935 href="http://dx.doi.org/10.1176/appi.ajp.2015.15040465">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d10202e944 class=n-a></a>Duman RS, Aghajanian GK, Sanacora G, <i> et al.</i>: Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. <i>Nat Med.</i> 2016; <b>22</b>(3): 238–49. <a target=xrefwindow id=d10202e955 href="http://www.ncbi.nlm.nih.gov/pubmed/26937618">PubMed Abstract </a> | <a target=xrefwindow id=d10202e958 href="http://dx.doi.org/10.1038/nm.4050">Publisher Full Text </a> | <a target=xrefwindow id=d10202e962 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5405628">Free Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d10202e971 class=n-a></a>McEwen BS, Eiland L, Hunter RG, <i> et al.</i>: Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress. <i>Neuropharmacology.</i> 2012; <b>62</b>(1): 3–12. <a target=xrefwindow id=d10202e982 href="http://www.ncbi.nlm.nih.gov/pubmed/21807003">PubMed Abstract </a> | <a target=xrefwindow id=d10202e985 href="http://dx.doi.org/10.1016/j.neuropharm.2011.07.014">Publisher Full Text </a> | <a target=xrefwindow id=d10202e989 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3196296">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d10202e998 class=n-a></a>Morrison JH, Baxter MG: The ageing cortical synapse: hallmarks and implications for cognitive decline. <i>Nat Rev Neurosci.</i> 2012; <b>13</b>(4): 240–50. <a target=xrefwindow id=d10202e1006 href="http://www.ncbi.nlm.nih.gov/pubmed/22395804">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1009 href="http://dx.doi.org/10.1038/nrn3200">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3592200">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717956648"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1021 class=n-a></a>Kang HJ, Voleti B, Hajszan T, <i> et al.</i>: Decreased expression of synapse-related genes and loss of synapses in major depressive disorder. <i>Nat Med.</i> 2012; <b>18</b>(9): 1413–7. <a target=xrefwindow id=d10202e1032 href="http://www.ncbi.nlm.nih.gov/pubmed/22885997">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1035 href="http://dx.doi.org/10.1038/nm.2886">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1039 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3491115">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717956648">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/5372956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1053 class=n-a></a>Li N, Lee B, Liu RJ, <i> et al.</i>: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. <i>Science.</i> 2010; <b>329</b>(5994): 959–64. <a target=xrefwindow id=d10202e1064 href="http://www.ncbi.nlm.nih.gov/pubmed/20724638">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1067 href="http://dx.doi.org/10.1126/science.1190287">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1071 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3116441">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/5372956">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/8778956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1084 class=n-a></a>Li N, Liu RJ, Dwyer JM, <i> et al.</i>: Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. <i>Biol Psychiatry.</i> 2011; <b>69</b>(8): 754–61. <a target=xrefwindow id=d10202e1095 href="http://www.ncbi.nlm.nih.gov/pubmed/21292242">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1098 href="http://dx.doi.org/10.1016/j.biopsych.2010.12.015">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1102 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3068225">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/8778956">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976903"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1115 class=n-a></a>Duman RS, Aghajanian GK: Synaptic dysfunction in depression: potential therapeutic targets. <i>Science.</i> 2012; <b>338</b>(6103): 68–72. <a target=xrefwindow id=d10202e1123 href="http://www.ncbi.nlm.nih.gov/pubmed/23042884">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1126 href="http://dx.doi.org/10.1126/science.1222939">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1129 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4424898">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976903">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732659544"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1142 class=n-a></a>Yang Y, Cui Y, Sang K, <i> et al.</i>: Ketamine blocks bursting in the lateral habenula to rapidly relieve depression. <i>Nature.</i> 2018; <b>554</b>(7692): 317–22. <a target=xrefwindow id=d10202e1153 href="http://www.ncbi.nlm.nih.gov/pubmed/29446381">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1156 href="http://dx.doi.org/10.1038/nature25509">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732659544">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d10202e1169 class=n-a></a>Moghaddam B, Adams B, Verma A, <i> et al.</i>: Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. <i>J Neurosci.</i> 1997; <b>17</b>(8): 2921–7. <a target=xrefwindow id=d10202e1180 href="http://www.ncbi.nlm.nih.gov/pubmed/9092613">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1183 href="http://dx.doi.org/10.1523/JNEUROSCI.17-08-02921.1997">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732838229"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1192 class=n-a></a>Widman AJ, McMahon LL: Disinhibition of CA1 pyramidal cells by low-dose ketamine and other antagonists with rapid antidepressant efficacy. <i>Proc Natl Acad Sci U S A.</i> 2018; <b>115</b>(13): E3007–E3016. <a target=xrefwindow id=d10202e1200 href="http://www.ncbi.nlm.nih.gov/pubmed/29531088">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1203 href="http://dx.doi.org/10.1073/pnas.1718883115">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1206 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5879689">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732838229">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/11807956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1220 class=n-a></a>Autry AE, Adachi M, Nosyreva E, <i> et al.</i>: NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. <i>Nature.</i> 2011; <b>475</b>(7354): 91–5. <a target=xrefwindow id=d10202e1231 href="http://www.ncbi.nlm.nih.gov/pubmed/21677641">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1234 href="http://dx.doi.org/10.1038/nature10130">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1238 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3172695">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/11807956">F1000 Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d10202e1251 class=n-a></a>Liu RJ, Lee FS, Li XY, <i> et al.</i>: Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. <i>Biol Psychiatry.</i> 2012; <b>71</b>(11): 996–1005. <a target=xrefwindow id=d10202e1262 href="http://www.ncbi.nlm.nih.gov/pubmed/22036038">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1265 href="http://dx.doi.org/10.1016/j.biopsych.2011.09.030">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1269 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3290730">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d10202e1278 class=n-a></a>Lepack AE, Fuchikami M, Dwyer JM, <i> et al.</i>: BDNF release is required for the behavioral actions of ketamine. <i>Int J Neuropsychopharmacol.</i> 2014; <b>18</b>(1): pii: pyu033. <a target=xrefwindow id=d10202e1289 href="http://www.ncbi.nlm.nih.gov/pubmed/25539510">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1292 href="http://dx.doi.org/10.1093/ijnp/pyu033">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1296 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4368871">Free Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d10202e1305 class=n-a></a>Kato T, Fogaça MV, Deyama S, <i> et al.</i>: BDNF release and signaling are required for the antidepressant actions of GLYX-13. <i>Mol Psychiatry.</i> 2017. <a target=xrefwindow id=d10202e1313 href="http://www.ncbi.nlm.nih.gov/pubmed/29203848">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1316 href="http://dx.doi.org/10.1038/mp.2017.220">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d10202e1325 class=n-a></a>Liu RJ, Fuchikami M, Dwyer JM, <i> et al.</i>: GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine. <i>Neuropsychopharmacology.</i> 2013; <b>38</b>(11): 2268–77. <a target=xrefwindow id=d10202e1336 href="http://www.ncbi.nlm.nih.gov/pubmed/23680942">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1339 href="http://dx.doi.org/10.1038/npp.2013.128">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1343 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3773678">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d10202e1352 class=n-a></a>Dwyer JM, Lepack AE, Duman RS: mTOR activation is required for the antidepressant effects of mGluR<sub>2/3</sub> blockade. <i>Int J Neuropsychopharmacol.</i> 2012; <b>15</b>(4): 429–34. <a target=xrefwindow id=d10202e1363 href="http://www.ncbi.nlm.nih.gov/pubmed/22114864">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1366 href="http://dx.doi.org/10.1017/S1461145711001702">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1370 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3580765">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d10202e1380 class=n-a></a>Yang C, Li WY, Yu HY, <i> et al.</i>: Tramadol pretreatment enhances ketamine-induced antidepressant effects and increases mammalian target of rapamycin in rat hippocampus and prefrontal cortex. <i>J Biomed Biotechnol.</i> 2012; <b>2012</b>: 175619. <a target=xrefwindow id=d10202e1391 href="http://www.ncbi.nlm.nih.gov/pubmed/22577289">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1394 href="http://dx.doi.org/10.1155/2012/175619">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1398 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3336144">Free Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d10202e1407 class=n-a></a>Carrier N, Kabbaj M: Sex differences in the antidepressant-like effects of ketamine. <i>Neuropharmacology.</i> 2013; <b>70</b>: 27–34. <a target=xrefwindow id=d10202e1415 href="http://www.ncbi.nlm.nih.gov/pubmed/23337256">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1418 href="http://dx.doi.org/10.1016/j.neuropharm.2012.12.009">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/723870771"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1427 class=n-a></a>Miller OH, Yang L, Wang CC, <i> et al.</i>: GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. <i>eLife.</i> 2014; <b>3</b>: e03581. <a target=xrefwindow id=d10202e1438 href="http://www.ncbi.nlm.nih.gov/pubmed/25340958">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1441 href="http://dx.doi.org/10.7554/eLife.03581">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1445 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4270067">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/723870771">F1000 Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d10202e1458 class=n-a></a>Paul RK, Singh NS, Khadeer M, <i> et al.</i>: (<i>R,S</i>)-Ketamine metabolites (<i>R,S</i>)-norketamine and (<i>2S,6S</i>)-hydroxynorketamine increase the mammalian target of rapamycin function. <i>Anesthesiology.</i> 2014; <b>121</b>(1): 149–59. <a target=xrefwindow id=d10202e1479 href="http://www.ncbi.nlm.nih.gov/pubmed/24936922">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1482 href="http://dx.doi.org/10.1097/ALN.0000000000000285">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1485 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4061505">Free Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d10202e1494 class=n-a></a>Zhou W, Wang N, Yang C, <i> et al.</i>: Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. <i>Eur Psychiatry.</i> 2014; <b>29</b>(7): 419–23. <a target=xrefwindow id=d10202e1505 href="http://www.ncbi.nlm.nih.gov/pubmed/24321772">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1508 href="http://dx.doi.org/10.1016/j.eurpsy.2013.10.005">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d10202e1517 class=n-a></a>Chiu CT, Scheuing L, Liu G, <i> et al.</i>: The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. <i>Int J Neuropsychopharmacol.</i> 2014; <b>18</b>(6): pii: pyu102. <a target=xrefwindow id=d10202e1528 href="http://www.ncbi.nlm.nih.gov/pubmed/25548109">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1531 href="http://dx.doi.org/10.1093/ijnp/pyu102">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1535 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4438544">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d10202e1545 class=n-a></a>Pazini FL, Cunha MP, Rosa JM, <i> et al.</i>: Creatine, Similar to Ketamine, Counteracts Depressive-Like Behavior Induced by Corticosterone via PI3K/Akt/mTOR Pathway. <i>Mol Neurobiol.</i> 2016; <b>53</b>(10): 6818–34. <a target=xrefwindow id=d10202e1556 href="http://www.ncbi.nlm.nih.gov/pubmed/26660117">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1559 href="http://dx.doi.org/10.1007/s12035-015-9580-9">Publisher Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d10202e1568 class=n-a></a>Zhang YH, Zhang J, Song JN, <i> et al.</i>: The PI3K-AKT-mTOR pathway activates recovery from general anesthesia. <i>Oncotarget.</i> 2016; <b>7</b>(27): 40939–52. <a target=xrefwindow id=d10202e1579 href="http://www.ncbi.nlm.nih.gov/pubmed/27340771">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1582 href="http://dx.doi.org/10.18632/oncotarget.10172">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1586 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5173033">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d10202e1595 class=n-a></a>Wang CQ, Ye Y, Chen F, <i> et al.</i>: Posttraumatic administration of a sub-anesthetic dose of ketamine exerts neuroprotection via attenuating inflammation and autophagy. <i>Neuroscience.</i> 2017; <b>343</b>: 30–8. <a target=xrefwindow id=d10202e1606 href="http://www.ncbi.nlm.nih.gov/pubmed/27916727">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1609 href="http://dx.doi.org/10.1016/j.neuroscience.2016.11.029">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d10202e1618 class=n-a></a>Rame M, Caudal D, Schenker E, <i> et al.</i>: Clozapine counteracts a ketamine-induced depression of hippocampal-prefrontal neuroplasticity and alters signaling pathway phosphorylation. <i>PLoS One.</i> 2017; <b>12</b>(5): e0177036. <a target=xrefwindow id=d10202e1629 href="http://www.ncbi.nlm.nih.gov/pubmed/28472198">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1632 href="http://dx.doi.org/10.1371/journal.pone.0177036">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1636 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5417651">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726084835"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1645 class=n-a></a>Harraz MM, Tyagi R, Cortés P, <i> et al.</i>: Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. <i>Mol Psychiatry.</i> 2016; <b>21</b>(3): 313–9. <a target=xrefwindow id=d10202e1656 href="http://www.ncbi.nlm.nih.gov/pubmed/26782056">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1659 href="http://dx.doi.org/10.1038/mp.2015.211">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1663 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4830355">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726084835">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726744921"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1676 class=n-a></a>Liu RJ, Duman C, Kato T, <i> et al.</i>: GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine. <i>Neuropsychopharmacology.</i> 2017; <b>42</b>(6): 1231–42. <a target=xrefwindow id=d10202e1687 href="http://www.ncbi.nlm.nih.gov/pubmed/27634355">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1690 href="http://dx.doi.org/10.1038/npp.2016.202">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1694 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5437877">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726744921">F1000 Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727754675"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1708 class=n-a></a>Yang C, Ren Q, Qu Y, <i> et al.</i>: Mechanistic Target of Rapamycin-Independent Antidepressant Effects of (<i>R</i>)-Ketamine in a Social Defeat Stress Model. <i>Biol Psychiatry.</i> 2018; <b>83</b>(1): 18–28. <a target=xrefwindow id=d10202e1722 href="http://www.ncbi.nlm.nih.gov/pubmed/28651788">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1726 href="http://dx.doi.org/10.1016/j.biopsych.2017.05.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727754675">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/731324148"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1739 class=n-a></a>Popp S, Behl B, Joshi JJ, <i> et al.</i>: In search of the mechanisms of ketamine’s antidepressant effects: How robust is the evidence behind the mTor activation hypothesis [version 1; referees: 1 approved, 1 approved with reservations] <i>F1000Res.</i> 2016; <b>5</b>: 634. <a target=xrefwindow id=d10202e1750 href="http://dx.doi.org/10.12688/f1000research.8236.1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/731324148">F1000 Recommendation</a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d10202e1763 class=n-a></a>Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? <i>Neuropsychopharmacology.</i> 2015; <b>40</b>(5): 1307. <a target=xrefwindow id=d10202e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/25767082">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1774 href="http://dx.doi.org/10.1038/npp.2014.338">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1777 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4367478">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726953465"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1786 class=n-a></a>Haroon E, Miller AH: Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. <i>Curr Top Behav Neurosci.</i> 2017; <b>31</b>: 173–98. <a target=xrefwindow id=d10202e1794 href="http://www.ncbi.nlm.nih.gov/pubmed/27830574">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1797 href="http://dx.doi.org/10.1007/7854_2016_40">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726953465">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d10202e1810 class=n-a></a>Sanacora G, Johnson MR, Khan A, <i> et al.</i>: Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study. <i>Neuropsychopharmacology.</i> 2017; <b>42</b>(4): 844–53. <a target=xrefwindow id=d10202e1821 href="http://www.ncbi.nlm.nih.gov/pubmed/27681442">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1824 href="http://dx.doi.org/10.1038/npp.2016.224">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1828 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5312066">Free Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d10202e1837 class=n-a></a>Zarate CA Jr, Singh JB, Quiroz JA, <i> et al.</i>: A double-blind, placebo-controlled study of memantine in the treatment of major depression. <i>Am J Psychiatry.</i> 2006; <b>163</b>(1): 153–5. <a target=xrefwindow id=d10202e1848 href="http://www.ncbi.nlm.nih.gov/pubmed/16390905">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1851 href="http://dx.doi.org/10.1176/appi.ajp.163.1.153">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d10202e1861 class=n-a></a>Sanacora G, Smith MA, Pathak S, <i> et al.</i>: Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. <i>Mol Psychiatry.</i> 2014; <b>19</b>(9): 978–85. <a target=xrefwindow id=d10202e1872 href="http://www.ncbi.nlm.nih.gov/pubmed/24126931">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1875 href="http://dx.doi.org/10.1038/mp.2013.130">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1879 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4195977">Free Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d10202e1888 class=n-a></a>Yang C, Shirayama Y, Zhang JC, <i> et al.</i>: <i>R</i>-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. <i>Transl Psychiatry.</i> 2015; <b>5</b>(9): e632. <a target=xrefwindow id=d10202e1902 href="http://www.ncbi.nlm.nih.gov/pubmed/26327690">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1906 href="http://dx.doi.org/10.1038/tp.2015.136">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1909 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5068814">Free Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726329216"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1918 class=n-a></a>Zanos P, Moaddel R, Morris PJ, <i> et al.</i>: NMDAR inhibition-independent antidepressant actions of ketamine metabolites. <i>Nature.</i> 2016; <b>533</b>(7604): 481–6. <a target=xrefwindow id=d10202e1929 href="http://www.ncbi.nlm.nih.gov/pubmed/27144355">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1932 href="http://dx.doi.org/10.1038/nature17998">Publisher Full Text </a> | <a target=xrefwindow id=d10202e1936 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4922311">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726329216">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d10202e1949 class=n-a></a>Fukumoto K, kato T, Li X-Y, <i> et al.</i>: Role of BDNF/mTORC1 signaling in the long-lasting antidepressant effects of (2R,6R)-hydroxynorketamine. <i>American College of Neuropsychopharmacology.</i> 2017</span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727226050"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e1964 class=n-a></a>Yang C, Qu Y, Abe M, <i> et al.</i>: (<i>R</i>)-Ketamine Shows Greater Potency and Longer Lasting Antidepressant Effects Than Its Metabolite (2<i>R</i>,6<i>R</i>)-Hydroxynorketamine. <i>Biol Psychiatry.</i> 2017; <b>82</b>(5): e43–e44. <a target=xrefwindow id=d10202e1985 href="http://www.ncbi.nlm.nih.gov/pubmed/28104224">PubMed Abstract </a> | <a target=xrefwindow id=d10202e1988 href="http://dx.doi.org/10.1016/j.biopsych.2016.12.020">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727226050">F1000 Recommendation</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732138182"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e2001 class=n-a></a>Shirayama Y, Hashimoto K: Lack of Antidepressant Effects of (2<i>R</i>,6<i>R</i>)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (<i>R</i>)-Ketamine. <i>Int J Neuropsychopharmacol.</i> 2018; <b>21</b>(1): 84–8. <a target=xrefwindow id=d10202e2019 href="http://www.ncbi.nlm.nih.gov/pubmed/29155993">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2022 href="http://dx.doi.org/10.1093/ijnp/pyx108">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2025 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5795355">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732138182">F1000 Recommendation</a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727744817"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e2039 class=n-a></a>Suzuki K, Nosyreva E, Hunt KW, <i> et al.</i>: Effects of a ketamine metabolite on synaptic NMDAR function. <i>Nature.</i> 2017; <b>546</b>(7659): E1–E3. <a target=xrefwindow id=d10202e2050 href="http://www.ncbi.nlm.nih.gov/pubmed/28640258">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2053 href="http://dx.doi.org/10.1038/nature22084">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727744817">F1000 Recommendation</a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a name=d10202e2066 class=n-a></a>Preskorn SH, Baker B, Kolluri S, <i> et al.</i>: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective <i>N</i>-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. <i>J Clin Psychopharmacol.</i> 2008; <b>28</b>(6): 631–7. <a target=xrefwindow id=d10202e2080 href="http://www.ncbi.nlm.nih.gov/pubmed/19011431">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2084 href="http://dx.doi.org/10.1097/JCP.0b013e31818a6cea">Publisher Full Text </a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d10202e2093 class=n-a></a>Ibrahim L, Diaz Granados N, Jolkovsky L, <i> et al.</i>: A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. <i>J Clin Psychopharmacol.</i> 2012; <b>32</b>(4): 551–7. <a target=xrefwindow id=d10202e2104 href="http://www.ncbi.nlm.nih.gov/pubmed/22722512">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2107 href="http://dx.doi.org/10.1097/JCP.0b013e31825d70d6">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2111 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3438886">Free Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d10202e2120 class=n-a></a>Maeng S, Zarate CA Jr, Du J, <i> et al.</i>: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. <i>Biol Psychiatry.</i> 2008; <b>63</b>(4): 349–52. <a target=xrefwindow id=d10202e2131 href="http://www.ncbi.nlm.nih.gov/pubmed/17643398">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2134 href="http://dx.doi.org/10.1016/j.biopsych.2007.05.028">Publisher Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726231243"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e2143 class=n-a></a>Moskal JR, Burgdorf JS, Stanton PK, <i> et al.</i>: The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant. <i>Curr Neuropharmacol.</i> 2017; <b>15</b>(1): 47–56. <a target=xrefwindow id=d10202e2154 href="http://www.ncbi.nlm.nih.gov/pubmed/26997507">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2157 href="http://dx.doi.org/10.2174/1570159X14666160321122703">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2161 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5327451">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726231243">F1000 Recommendation</a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d10202e2174 class=n-a></a>Burgdorf J, Zhang XL, Nicholson KL, <i> et al.</i>: GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. <i>Neuropsychopharmacology.</i> 2013; <b>38</b>(5): 729–42. <a target=xrefwindow id=d10202e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/23303054">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2188 href="http://dx.doi.org/10.1038/npp.2012.246">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3671991">Free Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726609768"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e2202 class=n-a></a>Yang B, Zhang JC, Han M, <i> et al.</i>: Comparison of <i>R</i>-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. <i>Psychopharmacology (Berl).</i> 2016; <b>233</b>(19–20): 3647–57. <a target=xrefwindow id=d10202e2216 href="http://www.ncbi.nlm.nih.gov/pubmed/27488193">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2220 href="http://dx.doi.org/10.1007/s00213-016-4399-2">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2223 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5021744">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726609768">F1000 Recommendation</a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d10202e2236 class=n-a></a>Preskorn S, Macaluso M, Mehra DO, <i> et al.</i>: Randomized proof of concept trial of GLYX-13, an <i>N</i>-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. <i>J Psychiatr Pract.</i> 2015; <b>21</b>(2): 140–9. <a target=xrefwindow id=d10202e2250 href="http://www.ncbi.nlm.nih.gov/pubmed/25782764">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2254 href="http://dx.doi.org/10.1097/01.pra.0000462606.17725.93">Publisher Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727219602"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d10202e2263 class=n-a></a>Garay RP, Zarate CA Jr, Charpeaud T, <i> et al.</i>: Investigational drugs in recent clinical trials for treatment-resistant depression. <i>Expert Rev Neurother.</i> 2017; <b>17</b>(6): 593–609. <a target=xrefwindow id=d10202e2274 href="http://www.ncbi.nlm.nih.gov/pubmed/28092469">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2277 href="http://dx.doi.org/10.1080/14737175.2017.1283217">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2281 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5418088">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727219602">F1000 Recommendation</a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a name=d10202e2294 class=n-a></a>Dwyer JM, Lepack AE, Duman RS: mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. <i>J Mol Psychiatry.</i> 2013; <b>1</b>(1): 15. <a target=xrefwindow id=d10202e2302 href="http://www.ncbi.nlm.nih.gov/pubmed/25408908">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2305 href="http://dx.doi.org/10.1186/2049-9256-1-15">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2308 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4224009">Free Full Text </a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d10202e2317 class=n-a></a>Koike H, Iijima M, Chaki S: Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. <i>Neuropharmacology.</i> 2011; <b>61</b>(8): 1419–23. <a target=xrefwindow id=d10202e2325 href="http://www.ncbi.nlm.nih.gov/pubmed/21903115">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2328 href="http://dx.doi.org/10.1016/j.neuropharm.2011.08.034">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d10202e2337 class=n-a></a>Furey ML, Drevets WC: Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. <i>Arch Gen Psychiatry.</i> 2006; <b>63</b>(10): 1121–9. <a target=xrefwindow id=d10202e2345 href="http://www.ncbi.nlm.nih.gov/pubmed/17015814">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2348 href="http://dx.doi.org/10.1001/archpsyc.63.10.1121">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2351 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3250308">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a name=d10202e2361 class=n-a></a>Drevets WC, Furey ML: Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. <i>Biol Psychiatry.</i> 2010; <b>67</b>(5): 432–8. <a target=xrefwindow id=d10202e2369 href="http://www.ncbi.nlm.nih.gov/pubmed/20074703">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2372 href="http://dx.doi.org/10.1016/j.biopsych.2009.11.021">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2375 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3264395">Free Full Text </a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a name=d10202e2384 class=n-a></a>Voleti B, Navarria A, Liu RJ, <i> et al.</i>: Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. <i>Biol Psychiatry.</i> 2013; <b>74</b>(10): 742–9. <a target=xrefwindow id=d10202e2395 href="http://www.ncbi.nlm.nih.gov/pubmed/23751205">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2398 href="http://dx.doi.org/10.1016/j.biopsych.2013.04.025">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2402 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3773272">Free Full Text </a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a name=d10202e2411 class=n-a></a>Ghosal S, Bang E, Yue W, <i> et al.</i>: Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine. <i>Biol Psychiatry.</i> 2018; <b>83</b>(1): 29–37. <a target=xrefwindow id=d10202e2422 href="http://www.ncbi.nlm.nih.gov/pubmed/28751069">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2425 href="http://dx.doi.org/10.1016/j.biopsych.2017.06.017">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2429 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5705490">Free Full Text </a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a name=d10202e2438 class=n-a></a>Wohleb ES, Wu M, Gerhard DM, <i> et al.</i>: GABA interneurons mediate the rapid antidepressant-like effects of scopolamine. <i>J Clin Invest.</i> 2016; <b>126</b>(7): 2482–94. <a target=xrefwindow id=d10202e2449 href="http://www.ncbi.nlm.nih.gov/pubmed/27270172">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2452 href="http://dx.doi.org/10.1172/JCI85033">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4922686">Free Full Text </a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a name=d10202e2465 class=n-a></a>Fischell J, Van Dyke AM, Kvarta MD, <i> et al.</i>: Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABA<sub>A</sub> Receptors. <i>Neuropsychopharmacology.</i> 2015; <b>40</b>(11): 2499–509. <a target=xrefwindow id=d10202e2479 href="http://www.ncbi.nlm.nih.gov/pubmed/25900119">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2483 href="http://dx.doi.org/10.1038/npp.2015.112">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2486 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4569955">Free Full Text </a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a name=d10202e2495 class=n-a></a>Zanos P, Nelson ME, Highland JN, <i> et al.</i>: A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice. <i>eNeuro.</i> 2017; <b>4</b>(1): pii: ENEURO.0285-16.2017. <a target=xrefwindow id=d10202e2506 href="http://www.ncbi.nlm.nih.gov/pubmed/28275719">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2509 href="http://dx.doi.org/10.1523/ENEURO.0285-16.2017">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2513 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5334634">Free Full Text </a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d10202e2523 class=n-a></a>Efeyan A, Comb WC, Sabatini DM: Nutrient-sensing mechanisms and pathways. <i>Nature.</i> 2015; <b>517</b>(7534): 302–10. <a target=xrefwindow id=d10202e2531 href="http://www.ncbi.nlm.nih.gov/pubmed/25592535">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2534 href="http://dx.doi.org/10.1038/nature14190">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2537 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4313349">Free Full Text </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a name=d10202e2546 class=n-a></a>Maguire J, Mody I: GABA<sub>A</sub>R plasticity during pregnancy: relevance to postpartum depression. <i>Neuron.</i> 2008; <b>59</b>(2): 207–13. <a target=xrefwindow id=d10202e2557 href="http://www.ncbi.nlm.nih.gov/pubmed/18667149">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2560 href="http://dx.doi.org/10.1016/j.neuron.2008.06.019">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2564 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2875248">Free Full Text </a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d10202e2573 class=n-a></a>Kanes S, Colquhoun H, Gunduz-Bruce H, <i> et al.</i>: Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. <i>Lancet.</i> 2017; <b>390</b>(10093): 480–9. <a target=xrefwindow id=d10202e2584 href="http://www.ncbi.nlm.nih.gov/pubmed/28619476">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2587 href="http://dx.doi.org/10.1016/S0140-6736(17)31264-3">Publisher Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a name=d10202e2596 class=n-a></a>Kanes SJ, Colquhoun H, Doherty J, <i> et al.</i>: Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression. <i>Hum Psychopharmacol.</i> 2017; <b>32</b>(2): e2576. <a target=xrefwindow id=d10202e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/28370307">PubMed Abstract </a> | <a target=xrefwindow id=d10202e2610 href="http://dx.doi.org/10.1002/hup.2576">Publisher Full Text </a> | <a target=xrefwindow id=d10202e2614 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5396368">Free Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 May 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-659/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-659/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Psychiatry, Laboratory of Molecular Psychiatry, Yale University School of Medicine, New Haven, CT 06508, USA<br/> <p> <div class=margin-bottom> Ronald S. Duman <br/> <span>Roles: </span> Formal Analysis </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/7-659/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 24 May 2018, 7:659 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.14344.1">https://doi.org/10.12688/f1000research.14344.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2018 Duman RS. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the <a href="http://creativecommons.org/publicdomain/zero/1.0/" target=_blank data-test-id=box-data-licence-link>Creative Commons Zero "No rights reserved" data waiver</a> (CC0 1.0 Public domain dedication). </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=15607 data-id=14344 data-downloads="" data-views="" data-scholar="10.12688/f1000research.14344.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/7-659/v1/pdf?article_uuid=86324d24-a4b1-425c-88fd-b613eccabdc8" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.14344.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide [version 1; peer review: 3 approved] <i>F1000Research</i> 2018, <b>7</b>(F1000 Faculty Rev):659 (<a href="https://doi.org/10.12688/f1000research.14344.1" target=_blank>https://doi.org/10.12688/f1000research.14344.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=14344 id=mobile-track-article-signin-14344 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/14344?target=/articles/7-659/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=15607 /> <input name=articleId type=hidden value=14344 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Kenji Hashimoto</strong>, Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Japan </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Dr. Hashimoto is an inventor on a filed patent application on "The use of (R)-ketamine in the treatment of psychiatric diseases" by Chiba University. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Dan V. Iosifescu</strong>, Nathan Kline Institute and New York University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Sanjay J Mathew</strong>, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, USA; Michael E. Debakey VA Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> Sanjay J. Mathew receives research support from Janssen and NeuroRx, and consulting fees from Allergan, Alkermes, and Fortress Biotech. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 24 May 2018</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/7-659/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/7-659/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=34698-34249></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=34699-34250></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=34697-34248></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/7-659/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>24 May 18</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Kenji Hashimoto</strong>, Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Japan </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Dr. Hashimoto is an inventor on a filed patent application on "The use of (R)-ketamine in the treatment of psychiatric diseases" by Chiba University. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dan V. Iosifescu</strong>, Nathan Kline Institute and New York University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Sanjay J Mathew</strong>, Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, USA; Michael E. Debakey VA Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> Sanjay J. Mathew receives research support from Janssen and NeuroRx, and consulting fees from Allergan, Alkermes, and Fortress Biotech. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/7-659/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/7-659/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Ketamine and rapid-acting antidepressants:...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/7-659/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/7-659/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/7-659/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Duman RS');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/7-659/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/7-659",
            templates : {
                twitter : "Ketamine and rapid-acting antidepressants: a new era in the battle.... Duman RS, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/7-659/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/14344/15607")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "15607");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "34246": 0,
                           "34247": 0,
                           "34248": 0,
                           "34249": 0,
                           "34250": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "6168c2c4-b554-48ae-be0d-84108f6e1ac1";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-659.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-659.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/7-659.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/7-659.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/7-659.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>